Cohort – Integrated multidisciplinary approach

Title of the cohort
Cohort – Integrated multidisciplinary approach
Acronym for cohort
AMI
Name of Principal Investigator

Title Professor
First name
Last name DARTIGUES

Address of institution where award is held

Institution
Street Address
City Bordeaux
Postcode 33076

Country

  • France

Website
www.isped.u-bordeaux2.fr
Contact email

Funding source

1. The cohort includes, or expects to include, incidence of the following conditions

  • Alzheimer’s disease and other dementias
  • Parkinson’s disease

When studies on the above condition(s) are expected to become possible

  • 2011 – 2015

2a. Stated aim of the cohort
Analysis of Alzheimer disease occurrence in a rural aged population of and comparison with urban population
2b. Features distinguishing this cohort from other population cohorts
The rural origin of the selected population
3a. i) Number of publications that involve use of cohort to date
0
3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)
prevalence of dementia, prevalence of dependency, happiness, life satisfaction
3b. Publication list/link to where data or publications are accessible (if available)

3c. Information (i.e. research findings) expected to be gained from the population cohort
The main goal is to know if a routinely pesticides using is prone to Alzheimer disease
4a. Study criteria: age range of participants at recruitment

Age in years from: 65
To (‘until death’ if applicable): until death

4b. Study criteria: inclusion criteria
over 65 years, retired people with an agricultural work before, living in a selected rural area of Gironde
4c. Study criteria: exclusion criteria
not over 65 years, not retired people with an agricultural work before, not living in a selected rural area of Gironde
5. Size of the cohort (i.e. number of participants enrolled)

  • 1,000 – 5,000 participants

6a. Measures used to characterise participants
age, gender, professional calendar (pesticides exposition), life conditions, reaction scale to life events, level of work complexity, preference scale of routinisation
6b. Additional measures for participants with a clinical disorder

6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)
###VALUE###
7. Study design

  • Prospective cohort

8. Cases matched by

  • Other health assessment (specify) / N/A
  • Dependency

9a. Does the study include a specialised subset of control participants

  • No

9b. If yes, description of specialised subset of control participants

10a. i) Data collection start date
01-09-2007
10a. ii) Data collection end date
01-01-2012
10a iii) Data collection for this study is

  • Data collection ongoing
  • Closed to new patients

10b. Plans to continue the cohort study beyond the current projected end date

  • Yes – intend to apply for funding

11. Data collected

  • Only through the study
  • Through links to other records or registers (such as dental records, police records etc). Please specify
  • MSA and Agrica Files

12. System in place to enable re-contact with patients for future studies

  • Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

13a. Format and availability of data stored in a database

Yes/No % available
Data summarised in database  Yes
Database is web-based  no
Database on spreadsheet
Database is on paper
Other (specify)

 
Language used:
French
13b. Format and availability of data held as individual records

Yes/No % available
Data held as individual records  yes
Data is web-based
Data held on computer based records
Data held on cards
Other (specify)

 
Language used:
French
14a. Are data available to other groups
No
15. Data sharing policy specified as a condition of use

  • Data made publicly available after a specified time point

16a. Are tissues/samples/DNA available to other groups
Yes
16b. i) Description of available tissues/samples/DNA

  • Living donors:blood
  • Living donors: blood derivatives
  • Living donors: DNA

16b. ii) Form available tissues/samples/DNA are supplied in

  • Primary Samples: Stabilised samples (frozen or fixed)
  • Secondary samples: derivatives of primary samples
  • Secondary samples: plasma
  • Secondary samples: DNA

16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data
Yes
17. Is information on biological characteristics available to other groups

  • No

Cohort – Integrated multidisciplinary approach

Population Cohorts
France
Alzheimer’s disease & other dementias|Parkinson’s disease & PD-related disorders
2011

 

 

Post
Filter